Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evaluation
Latest Information Update: 29 Jul 2024
Price :
$35 *
At a glance
- Drugs NLS VPAC1 (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Diagnostic use
- 23 Jul 2024 Status changed from active, no longer recruiting to completed.
- 02 Jun 2023 Planned End Date changed from 1 Jan 2023 to 1 Apr 2024.
- 13 Dec 2022 Planned End Date changed from 30 Jan 2022 to 1 Jan 2023.